Rosiglitazone (Avandia) vs. Placebo for Androgen Dependent Prostate Cancer

Phase 3CompletedNCT00182052

Massachusetts General Hospital100 enrolled

Overview

The purpose of this study it to learn the effects (good or bad) that rosiglitazone has on patients and their prostate cancer. This study is going to look at what effects rosiglitazone has on prostate specific antigen (PSA) levels.

* Patients will be randomly assigned to initial treatment with either rosiglitazone or placebo orally twice daily, every day as long as there is no disease progression or serious side effects. Patients will be asked to complete a drug log to keep track of the medication. * Before treatment begins the following tests will be performed: physical exam; bone scan; blood work (including PSA level test) and a urine sample. * While on this study the following tests and procedures will be done once a month: review of side effects and routine blood tests (including PSA levels). * While on this study the following tests and procedures will be done on months 2 and 4: review of side effects; routine blood tests (including PSA levels) and urine tests. * If the patient's disease progressed the treatment code will be broken and if the patient was on placebo, they will have the option to begin taking rosiglitazone.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

DOUBLE

Enrollment

100

Conditions

Adenocarcinoma of the Prostate Prostate Cancer

Interventions

RosiglitazoneDRUG

Given orally twice daily. Participants may continue study treatment as long as their disease does not progress and they don't experience any serious side effects.

PlaceboOTHER

Given orally twice daily.

Eligibility

Sex: MALEMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Histologically confirmed adenocarcinoma of the prostate * Biochemical disease progression following local therapy defined as three rises in PSA with each PSA determination at least 4 weeks apart and each PSA value \> or = 0.2ng/ml * For men treated with radical prostatectomy, PSA \> or = 2 ng/ml * For men treated with primary radiation therapy or post-prostatectomy radiation therapy, PSA \> or = 2 ng/ml and \> 150% post-radiation nadir * Not an appropriate candidate for salvage radiation therapy or salvage prostatectomy * Baseline PSADT \< 24 months * CALGB performance status of 0,1 or 2 Exclusion Criteria: * Metastatic disease * Prior hormonal therapy for recurrent prostate cancer * Prior chemotherapy for prostate cancer * Current treatment with insulin or an oral hypoglycemic * History of treatment with thiazolidinediones * Radiation therapy within 6 months * SGOT \> 1.5 x ULN * Fasting blood glucose \< 60 mg/dl * NYHA Class 3 or 4 cardiac status

Locations (2)

Massachusetts General Hospital

Boston, Massachusetts, United States

Dana-Farber Cancer Institute

Boston, Massachusetts, United States

Outcomes

Primary Outcomes

To evaluate the activity of rosiglitazone by comparing changes in PSA doubling time between rosiglitazone-treated and placebo-treated men.

Time frame: 3 years

Secondary Outcomes

Evaluate time to PSA progression as a measure of the activity of rosiglitazone.

Time frame: 3 years

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.